Paras Healthcare Limited IPO is fully book build issue and it includes both Fresh Issue and OFS. Fresh issue size is ₹400.00 crores and offer for sale upto 14,97,40,10 shares.
The dates for the Paras Healthcare IPO have not been announced yet.
The allotment process is expected to be finalized by [.]. The Paras Healthcare IPO is scheduled to list on BSE, NSE, with a tentative listing date of [.].
The price band for the Paras Healthcare IPO has not been announced yet.
Registrar for this IPO is Link Intime India Private Limited and lead managers for Paras Healthcare IPO are ICICI Securities Limited, IIFL Securities Limited, Motilal Oswal Investment Advisors Limited.
IPO Schedule
| IPO Open Date | - |
|---|---|
| IPO Close Date | - |
| IPO Allotment Date | - |
| Refund Initiation | - |
| Share credit in Demat | - |
| Listing Date | - |
Key Details
| Price Band | TBA |
|---|---|
| Lot Size | TBA |
| Face Value | ₹1 Per Equity Share |
| Total Issue Size | 14,974,010 Shares + ₹400 Crores |
| Fresh Issue | ₹400.00 Crores |
| OFS Issue | 14,974,010 Shares |
| Issue Type | Fresh Issue and Offer for Sale |
| Listing At | BSE, NSE |
Share Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB | 75% |
| Retail | 10% |
| NII/HNI | 15% |
About Paras Healthcare Limited Company
Paras Health is the fifth largest healthcare provider in North India, Bihar, and Jharkhand, boasting 2,135 beds as of March 31, 2024. With eight hospitals operating under the "Paras Health" brand, the company has a presence across five states and one union territory.
The group strategically focuses on delivering specialized tertiary medical care in Tier 2 and 3 cities, balancing quality healthcare services with affordability. Key clinical specialties include cardiac sciences, oncology, neurosciences, gastro sciences, and orthopedics.
Paras Health has established centers of excellence within its hospitals, driving the launch of innovative programs like organ transplants. With 18 years of experience in North India, Paras Health possesses a strong understanding of regional market dynamics. The company reported the second highest year-on-year revenue growth of 23.00% with revenue increasing from ₹917.92 crore in Fiscal 2023 to ₹1,129.04 crore in Fiscal 2024.
Paras Healthcare Limited Financial Details
| Particulars | March 2024 | March 2023 | March 2022 |
|---|---|---|---|
| Total Assets | 1,477.66 | 1,293.10 | 963.53 |
| Total Revenue | 1,151.02 | 936.05 | 793.17 |
| Profit After Tax | -15.33 | -42.79 | -14.81 |
| Net Worth | 338.51 | 30.11 | 73.11 |
| Total Borrowings | 538.70 | 392.94 | 214.94 |
₹ In Crore
Key Performance Indicator
| Basic EPS (in ₹) | Return on Net Worth (RoNW) | Net Asset Value (NAV) | Debt-Equity Ratio | Return on Equity (ROE) | Return on Capital Employed (ROCE) |
|---|---|---|---|---|---|
| (1.57) | (8.32) | 34.68 |
Offer Objectives
The Promoter has agreed not to dispose of or encumber the Promoter's Contribution until the lock-in period specified by SEBI ICDR Regulations expires. The Equity Shares offered for Promoter’s Contribution do not include shares acquired through revaluation of assets, capitalization of intangible assets, or bonus issues from revaluation reserves. Also, the shares were not acquired in the preceding year at a price lower than the IPO offer price, and no shares have been issued pursuant to conversion from partnership firms in the preceding year.
The entire pre-Offer Equity Share capital (excluding Promoter's Contribution and Promoter's shareholding exceeding 20% of post-Offer equity, locked in for one year) will be locked in for six months from the date of Allotment, excluding shares transferred via Offer for Sale and shares allotted to eligible employees under ESOP 2024. 50% of Equity Shares allotted to Anchor Investors will have a 90-day lock-in, and the remaining 50% will have a 30-day lock-in from the Allotment date.
Locked-in shares held by the Promoter may be pledged with specific financial institutions as collateral for loans financing the Offer's objectives. Transfers of locked-in shares among Promoter Group members are allowed, subject to continued lock-in. As of the Draft Red Herring Prospectus date, the major shareholders are Dr. Dharminder Kumar Nagar holding 7,351.92 lakh shares (75.32%) and Commelina Ltd holding 2,409.14 lakh shares (24.68%).
The company may consider a Pre-IPO Placement, not exceeding 20% of the Fresh Issue size. A maximum of 21.96 lakh options may be issued under ESOP 2024, not exceeding 2.25% of the total paid-up capital.
The Offer includes both an Offer for Sale and a Fresh Issue. The company will not receive any proceeds from the Offer for Sale. The gross proceeds from the Fresh Issue are estimated at ₹400 crore. The Net Proceeds will be used for:
- Prepayment of outstanding borrowings of ₹217.96 crore
- Investment in Subsidiaries of ₹82.04 crore
- General corporate purposes, not exceeding 25% of the Gross Proceeds
Company Details
Address:
1st Floor, Tower B, Paras Twin Towers, Golf Course Road, Sector 54, Gurugram 122 002, Haryana, India
Phone: +91 124 430 2163
Email: [email protected]
Website: http://www.parashospitals.com
IPO Registrar Details
Link Intime India Private Limited
Phone: +91 810 811 4949
Email: [email protected]
Website: http://www.linkintime.co.in
Offer Prospectus & Documents
Lead Managers
- ICICI Securities Limited
- IIFL Securities Limited
- Motilal Oswal Investment Advisors Limited
